And taxpayers are footing most of the bill.
J&J gets nearly half of its $76 billion in revenue from medications like Tylenol and cancer-fighing drugs.
Good idea or bad idea?
Only 5 out of 100 programs that start at the discovery stage make it to patients.
Macroeconomic pressures have hit the R&D returns of life sciences firms.
"This guy has become a household name..."